Research and Markets has announced the addition of the "Outlook of Global Cancer Immunotherapy Outsourcing Market - Immunotherapy Discovery and Manufacturing Outsourcing" report to their offering.
The current global discovery outsourcing market of cancer immunotherapy is about $2.8 B. In the past five years (2010 - 2014), its CAGR was about 37%. Based on analysis, Research and Markets forecast that the global cancer immunotherapy-focused drug discovery outsourcing market will likely grow in a CAGR of 18% between 2015 and 2020 and may reach $7.56 B by 2020.
The global manufacturing outsourcing market of all types of cancer immunotherapy products has been experiencing a CAGR of about 12% in the past five years. Its current market size is estimated at around $1.9 B. Based on analysis, Research and Markets forecast that the global manufacturing outsourcing market of cancer immunotherapy products will likely experience a CAGR of 15% in the following six years and could reach around $4.4 B by 2020.
Cancer immunotherapy has been gaining increasing attention among all types of drug companies. It is widely considered one of the most effective ways to combat cancer. It has thus become the primary focus at present among all drug companies that have oncology R&D programs.
As the industry has become increasingly competitive, drug companies are increasingly looking to those biotechnology companies that possess the most advanced cutting-edge technologies to speed up their R&D programs in order to have a firm position in this competitive market. Accompanying the growth of the R&D activities are their growing outsourcing service demands for both discovery research and clinical trial material manufacturing to support their programs.
The report provides a complete picture of the global cancer immunotherapy outsourcing market in both discovery research and contract manufacturing and the unique insights of its future growth potentials. It is a must-read book to all pharmaceutical and biotechnology companies that seek outsourcing opportunities in cancer immunotherapy R&D and manufacturing, outsourcing service providers involved in this field that need to conceive their future business development directions, and venture capital investors that are looking for investment opportunities in this pharmaceutical industrial sector.